Mice injected with glioma cells engineered to overexpress VEGFC showed longer survival and smaller tumor volumes in response to immune checkpoint inhibition compared to mice bearing control gliomas (Hu et al. 2020). This evidence concerns the gene VEGFC and neoplasm.